Breakthroughs and Battles in the Global Health Arena

Breakthroughs and Battles in the Global Health Arena

Breakthroughs and Battles in the Global Health Arena Eli Lilly's novel obesity drug has demonstrated superior weight-loss results compared to its predecessor, Zepbound, in a late-stage trial, cementing the company's dominance in an expanding market. The escalating demand for GLP-1-based drugs has pharmaceutical firms rapidly investing in advanced treatments that promise greater efficacy.The weight-loss pharmaceutical market is on the verge of ex…